Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Sailen Barik & Vira Bitko. (2006) Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opinion on Biological Therapy 6:11, pages 1151-1160.
Read now
Read now
Andrea Savarino, Canio Buonavoglia, Sandro Norelli, Livia Di Trani & Antonio Cassone. (2006) Potential therapies for coronaviruses. Expert Opinion on Therapeutic Patents 16:9, pages 1269-1288.
Read now
Read now
Articles from other publishers (22)
Krittika Chatterjee, Sagheerah Lakdawala, Sheikh Shahnawaz Quadir, Dinesh Puri, Dinesh Kumar Mishra, Garima Joshi, Sanjay Sharma & Deepak Choudhary. (2023) siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight. AAPS PharmSciTech 24:6.
Crossref
Crossref
Assirbad Behura, Lincoln Naik, Salina Patel, Mousumi Das, Ashish Kumar, Abtar Mishra, Dev Kiran Nayak, Debraj Manna, Amit Mishra & Rohan Dhiman. (2023) Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1869:3, pages 166634.
Crossref
Crossref
Samir Kumar Patra & Moshe Szyf. (2022) Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic control. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1868:12, pages 166527.
Crossref
Crossref
Meng-Xin Chen, Xiao-Dong Zhu, Hao Zhang, Zhen Liu & Yuan-Ning Liu. (2022) SMRI: A New Method for siRNA Design for COVID-19 Therapy. Journal of Computer Science and Technology 37:4, pages 991-1002.
Crossref
Crossref
Seyedeh Hoda Alavizadeh, Maham Doagooyan, Fatemeh Zahedipour, Shima Yahoo Torghabe, Bahare Baharieh, Firooze Soleymani & Fatemeh Gheybi. (2022) Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID‐19. IET Nanobiotechnology 16:3, pages 67-77.
Crossref
Crossref
Sabrina Ferreira de Jesus, Laércio Ives Santos, João Felício Rodrigues Neto, Thallyta Maria Vieira, João Batista Mendes, Marcos Flavio Silveira Vasconcelos D'angelo & André Luiz Sena Guimaraes. (2021) Therapeutic perceptions in antisense RNA-mediated gene regulation for COVID-19. Gene 800, pages 145839.
Crossref
Crossref
Adi Idris, Alicia Davis, Aroon Supramaniam, Dhruba Acharya, Gabrielle Kelly, Yaman Tayyar, Nic West, Ping Zhang, Christopher L.D. McMillan, Citradewi Soemardy, Roslyn Ray, Denis O’Meally, Tristan A. Scott, Nigel A.J. McMillan & Kevin V. Morris. (2021) A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Molecular Therapy 29:7, pages 2219-2226.
Crossref
Crossref
Parichehr Hassanzadeh. (2021) The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing. Life Sciences 274, pages 119289.
Crossref
Crossref
Keith Johnson. (2021) Cosmology, astrobiology and the RNA world: just add quintessential water. International Journal of Astrobiology 20:2, pages 111-124.
Crossref
Crossref
Mohammad Reza Kalhori, Fatemeh Saadatpour, Ehsan Arefian, Masoud Soleimani, Mohammad Hosien Farzaei, Ina Yosifova Aneva & Javier Echeverría. (2021) The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection. Frontiers in Pharmacology 12.
Crossref
Crossref
Ahmed Donia & Habib Bokhari. (2020) RNA interference as a promising treatment against SARS-CoV-2. International Microbiology 24:1, pages 123-124.
Crossref
Crossref
Devasena T.Devasena T.. 2021. Nanotechnology-COVID-19 Interface. Nanotechnology-COVID-19 Interface
11
24
.
Keith Johnson. 2021. Water in Biomechanical and Related Systems. Water in Biomechanical and Related Systems
37
67
.
Hossein Aghamollaei, Rahim Sarvestani, Hamid Bakherad, Hamed Zare, Paul C. Guest, Reza Ranjbar & Amirhossein Sahebkar. 2021. Clinical, Biological and Molecular Aspects of COVID-19. Clinical, Biological and Molecular Aspects of COVID-19
81
96
.
Sandra Atlante, Alessia Mongelli, Veronica Barbi, Fabio Martelli, Antonella Farsetti & Carlo Gaetano. (2020) The epigenetic implication in coronavirus infection and therapy. Clinical Epigenetics 12:1.
Crossref
Crossref
Parichehr Hassanzadeh. (2020) Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. Journal of Controlled Release 328, pages 112-126.
Crossref
Crossref
Antonella Baldassarre, Alessandro Paolini, Stefania Paola Bruno, Cristina Felli, Alberto Eugenio Tozzi & Andrea Masotti. (2020) Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5’UTR of SARS-CoV-2. Epigenomics 12:15, pages 1349-1361.
Crossref
Crossref
Hasan Uludağ, Kylie Parent, Hamidreza Montazeri Aliabadi & Azita Haddadi. (2020) Prospects for RNAi Therapy of COVID-19. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Crossref
Kenneth Lundstrom. (2020) Coronavirus Pandemic—Therapy and Vaccines. Biomedicines 8:5, pages 109.
Crossref
Crossref
I. Krulko, D. Ustyanenko & V. Polischuk. (2009) Role of siRNAs and miRNAs in the processes of RNA-mediated gene silencing during viral infections. Cytology and Genetics 43:1, pages 63-72.
Crossref
Crossref
C.-Y. Lu, H.-Y. Huang, T.-H. Yang, L.-Y. Chang, C.-Y. Lee & L.-M. Huang. (2008) siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells. European Journal of Clinical Microbiology & Infectious Diseases 27:8, pages 709-715.
Crossref
Crossref
Kevin B. Spurgers, C. Matthew Sharkey, Kelly L. Warfield & Sina Bavari. (2008) Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Research 78:1, pages 26-36.
Crossref
Crossref